Lin H M, Kauffman H M, McBride M A, Davies D B, Rosendale J D, Smith C M, Edwards E B, Daily O P, Kirklin J, Shield C F, Hunsicker L G
United Network for Organ Sharing, Richmond, VA 23220, USA.
JAMA. 1998 Oct 7;280(13):1153-60. doi: 10.1001/jama.280.13.1153.
Multiple comprehensive, risk-adjusted studies evaluating short-term surgical mortality have been reported previously. This report analyzes short-term and long-term outcomes, both nationally and at each individual transplant program, for all solid organ transplantations performed in the United States.
To report graft and patient survival rates for all solid organ transplantations, both nationally and at each specific transplant program in the United States, and to compare the expected survival rate with the actual survival rate of each individual program.
Multivariate regression analysis of donor and recipient factors affecting graft and patient survival of all kidney, liver, pancreas, heart, lung, and heart-lung transplants reported to the United Network for Organ Sharing from 742 separate transplant programs.
A cohort of 97587 solid organ transplantations performed on 92966 recipients in the United States from January 1988 through April 1994.
Short-term and conditional 3-year national and individual transplant program graft and patient survival rates overall and from 2 separate eras (era 1, January 1988-April 1992; era 2, May 1992-April 1994); comparison of actual center-specific performance with risk-adjusted expected performance and identification of centers with better-than-expected or worse-than-expected survival rates.
One-year graft follow-up exceeded 98% and conditional 3-year follow-up exceeded 91% for all organs. Graft and patient survival improved significantly in era 2 compared with era 1 for all cadaver organs except heart, which remained the same. One-year cadaveric graft survival ranged from 81.5% for heart to 61.9% for heart-lung and 3-year conditional graft survival ranged from 91.3% for pancreas to 74.7% for lung. The percentage of programs whose actual 1-year graft survival was not different from or was better than their risk-adjusted expected survival ranged from 98.3% for heart-lung to 75.7% for liver. Most kidney, liver, and heart programs whose actual survival was significantly less than expected performed small numbers (less than the national average) of transplantations per year.
Graft and patient survival for solid organ transplantations showed improvement over time. Conditional 3-year graft and patient survival rates were approximately 90% for all organs except for lung and heart-lung. The conditional 3-year survival rates were better than 1-year survival rates, indicating the major risk after transplantation occurs in the first year. The majority of transplant programs achieved actual survival rates not significantly different from their expected survival rates. Center effects were most significant within the first year after transplantation and had much less influence on long-term survival outcomes.
此前已有多项全面的、经过风险调整的研究报告了短期手术死亡率。本报告分析了美国所有实体器官移植的短期和长期结果,包括全国范围以及每个单独的移植项目的情况。
报告美国全国以及每个特定移植项目中所有实体器官移植的移植物和患者生存率,并比较每个项目的预期生存率与实际生存率。
对742个不同移植项目向器官共享联合网络报告的所有肾、肝、胰、心、肺及心肺移植中影响移植物和患者生存的供体和受体因素进行多变量回归分析。
1988年1月至1994年4月在美国对92966名受者进行的97587例实体器官移植队列。
短期和有条件的3年全国及各移植项目的移植物和患者总体生存率,以及两个不同时期(时期1,1988年1月至1992年4月;时期2,1992年5月至1994年4月)的生存率;将各中心的实际表现与风险调整后的预期表现进行比较,并确定生存率高于或低于预期的中心。
所有器官的1年移植物随访率超过98%,有条件的3年随访率超过91%。除心脏生存率保持不变外,时期2与时期1相比,所有尸体器官的移植物和患者生存率均显著提高。尸体器官的1年移植物生存率从心脏的81.5%到心肺的61.9%不等,3年有条件移植物生存率从胰腺的91.3%到肺的74.7%不等。实际1年移植物生存率与风险调整后的预期生存率无差异或更好的项目比例,从心肺的98.3%到肝脏的75.7%不等。大多数实际生存率显著低于预期的肾、肝和心脏项目每年进行的移植数量较少(低于全国平均水平)。
实体器官移植的移植物和患者生存率随时间有所提高。除肺和心肺外,所有器官的有条件3年移植物和患者生存率约为90%。有条件的3年生存率优于1年生存率,表明移植后的主要风险发生在第一年。大多数移植项目的实际生存率与预期生存率无显著差异。中心效应在移植后第一年最为显著,对长期生存结果的影响则小得多。